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In clinical practice and screening programs, variations between one equation and 
another, specifically in early stages of CKD, should be considered.
PUK3
Patient Benefits and Cost savings PrediCted for MineraloCortiCoid-
reCePtor antagonist treatMent of early and advanCed diaBetiC 
Kidney disease
Blankenburg M1, Pelkey R2, Folse HJ2
1Bayer HealthCare Pharmaceuticals, Berlin, Germany, 2Evidera, San Francisco, CA, USA
Objectives: Exploratory studies suggest that mineralocorticoid-receptor antago-
nists (MRAs) may improve outcomes in patients with diabetic kidney disease (DKD). 
Finerenone (BAY 94-8862) is a selective, potent and non-steroidal MRA for the treat-
ment of patients with DKD, currently studied in two clinical phase III trials. Early 
modeling investigated the implications of using finerenone in addition to standard 
of care. MethOds: A Markov cohort model was used to emulate disease history, 
treatment effects, and outcomes for DKD patients with various disease severi-
ties (by albuminuria, measured by urinary-albumin-creatinine ratio [UACR], and 
chronic kidney disease [CKD] stage, measured by estimated glomerular filtration 
rate [eGFR]). Efficacy of finerenone is accomplished by reducing UACR, evidenced by 
phase 2 trial data. The model has UK settings; inputs are from NHANES 1999-2008, 
adapted to UK population, USRDS 2009, various registries, and trials. Sensitivity 
analyses explored which patient subpopulation would benefit to what extent from 
finerenone treatment. Results: The model predicts that finerenone is an effective 
treatment option for DKD patients, primarily by virtue of reduced risk of end-stage 
renal disease (ESRD) and renal death (absolute risk reductions [ARR] of up to 8.3% 
and 8.2%, respectively, for advanced DKD, i.e. macro-albuminuria and CKD3/4) and 
increased health-related quality of life, and that it would generate cost savings on 
renal replacement therapy (up to £5,353 for advanced DKD). From a clinical out-
comes perspective the optimal time point to begin finerenone treatment appears 
to be after patients have progressed to either macro-albuminuria or CKD stage 3, as 
represented by both phase III trial populations. Reduced CV events and CV mortality, 
however, are greatest (ARR of up to 3.7% and 4.7%, respectively) when finerenone 
treatment is started in CKD stages 3 or earlier. cOnclusiOns: Treatment with the 
MRA finerenone appears to be of significant benefit to patients and the healthcare 
system, particularly if initiated in advanced stages of DKD.
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data Mining Based on real World data in ChroniC Kidney disease 
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Objectives: The aim of the OCEANE non interventional study was to describe in real 
life conditions the management of anaemia with C.E.R.A. in patients with chronic 
kidney disease not on dialysis. We used data from this study to perform exploratory 
analysis to evaluate factors influencing haemoglobin levels. MethOds: To iden-
tify these factors, supervised and unsupervised data mining models and statisti-
cal approaches such as Random forest, hypercube analysis, Bayesian networks and 
mixed model for repeated measures were used. For supervised analysis, the targeted 
outcome measure was the haemoglobin level around 6 month of treatment, using 
EMA guidelines (haemoglobin level between [10-12] g/dL). As treatment patterns are 
very different, analyses have been performed by subgroup of patient naïve or not of 
ESA. Patients were followed up every 3 months during 1 year. Results: 616 adult 
patients were included/followed in the OCEANE study between 2009 and 2011, 609 
patients were taken into account for these analyses (haemoglobin available at base-
line) and 44% were ESA-naïve. 44% of patients without transfusion had a haemoglobin 
level within 10–12 g/dL around 6 months of treatment. For ESA-naïve patients, most 
patients with a haemoglobin level lower than 10 g/dL at 3 months remained below the 
target at 6 months. Regarding non ESA-naïve patients, most patients with a haemo-
globin level greater than 12 g/dL at 3 months remained above the target at 6 months. 
Dose adjustments were not performed for 2/3 of patients around 3 months when 
haemoglobin was outside the target range. cOnclusiOns: These techniques on real 
world data seems to be a way to broaden the pathology, compound and practice pat-
terns interactions. Dose adjustment around 3 months of treatment is a key factor for 
achieving the recommended haemoglobin target after 6 months. Our study confirms 
the importance of personalized anaemia management based on the patient’s profile.
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Objectives: This study aims to determine the patterns of medication use in 
patients with chronic kidney disease (CKD) stage 5D with special focus on drugs 
for the management of chronic kidney disease-mineral and bone disorder (CKD-
MBD). MethOds: A retrospective, observational study was conducted at Hospital 
Universiti Sains Malaysia. Medical records of 134 adult patients with CKD stage 5D 
were reviewed from January-April, 2014. Data regarding patient’s demographics, 
co-morbidities and medications were collected. The medications prescribed were 
classified according to the Anatomic Therapeutic Chemical classification recom-
mended by World Health Organization. The drugs were further categorized as clinic 
and home medications. Comparisons were made between age groups (≤ 50 or > 50 
years), gender and diabetic status. Results: Patients were 52.97 ± 14.05 years old, 
and were prescribed 12.88 ± 4.14 medications (10.00 ± 2.88 home medications and 
2.88 ± 2.99 clinic medications). Patient’s gender had no influence on the number of 
prescribed medications. However, patients with diabetes and elderly patients were 
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Objectives: To determine the prescribing pattern of specialized physicians for 
tuberculosis in Punjab, Pakistan. MethOds: A drug utilization study was conducted 
at community pharmacies among tuberculosis patients attending tertiary hospitals. 
A stratified sampling technique was used for selecting community pharmacies. 
Prescriptions written by tuberculosis specialized physicians were collected and 
analyzed according to WHO standard treatment guidelines. Results: The data 
were gathered from 750 prescriptions. Unfair number of drugs were prescribed 
in which the mean number of drugs in a single prescription was 7.0 (+2.1). The 
value of prescribing indicators was more than the WHO standard indicators. Most 
of the prescribed medicines (95%) were written in their brand names. Moreover, 
the frequently prescribed medicines were antibiotics (37.7%); anxiolytics (23.5%); 
and corticosteroids (29%). cOnclusiOns: Physicians’ adherence to the standard 
practicing guidelines was poor although the affordability of medicines was fair but 
still the prescribing pattern needs to be apposite. Implementation of administra-
tive strategies to improve the current prescribing pattern as well as patient-educa-
tional programs concerning the tuberculosis treatment are of utmost importance. 
In addition, further studies are required in other provinces of Pakistan in order to 
understand the complete prescribing behavior of the physician to treat tuberculosis 
throughout the country.
Urinary/Kidney disorders – Clinical outcomes studies
PUK1
CyClosPorine is not the drUg of ChoiCe for renal transPlanted 
Patients and inCreases the risK of CardiovasCUlar and 
CereBrovasCUlar aCCidents
Fazal J
Uinversita’ della Calabria, Cosenza, Italy
Objectives: The aim of the study was to investigate 1) if the average Pakistanis and 
average Italian kidney post transplanted patients have same episodes of adverse 
events after intake of cyclosporine,tacrolimus and corticosteroids 2) and to green 
light the safest as well as hazardous drug among these three with appropriate rea-
sons for effectiveness and ineffectiveness. MethOds: The subjects were randomly 
selected including 706 pakistani and 568 italian patients both male and female with 
inclusion criteria of teen age and geriatric patients.Blood sample was taken from 
each subject in order to determine the amount of creatinine,glucose,hemoglobin 
and cholesterol.Urine sample was also taken in order to determine level of pro-
tein.Also Delayed Graft Function (DFG) was observed in these subjects. Results: 
Thirty one percent of Italian men and 26% of Italian women suffered from hyper-
creatininemia and hyperproteinuria including hemoglobinemia and hyper-
cholesterolemia whereas 22% of Pakistani men and 21.50% of Pakistani women 
experienced same adverse effects.It was observed that majority of adverse effects 
were found between age group 46-55 and found to be least between age group 
17-25. cOnclusiOns: It was concluded that for immuno-compromised patients 
DGF,mortality rate and risk of transplant failure has been shown minimum for 
corticosteroids,intermediate for tacrolimus and maximum for cyclosporine and 
for immuno-competent patients,tacrolimus was effective drug. As cyclosporine 
which is composed of 11-amino acids,is followed by a competitive receptor bind-
ing with proteins whose level exceeds the upper limit in abnormal kidney function 
and hence those amino acids having same ‘R’ functionality with attaching side 
of cyclosporine will compete leading to unavailability of cyclosporine.Also it was 
observed that patient’s adherence was maximum with corticosteroids as they pro-
duce synergistic effect with adrenal gland’s steroid production.These data suggest 
that immuno-suppressants should be monitored with special care depending upon 
the immune status of patient.
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Objectives: In order to determine the GFR different equations had been used, 
mainly CG, the MDRD and CKD-EPI; with differences in estimation of renal func-
tion by these equation, therefore we defined to determine the correlation between 
these to estimate GFR in patients with hypertension (HT), diabetes (DM) or some 
stage of chronic kidney disease (CKD). MethOds: Data from 3.055.568 patients 
over 18 years with HT, DM and CKD was used. Prediction limits for differences 
between pairs of measurements using the limits according to Bland and Altman 
were calculated and plotted, the valuesLin correlation coefficients between MDRD- 
CG, CG-CKD/EPI and CKD/EPI-MDRD couples, considering that the three methods 
provide results measurement in the same scale. Results: 1.348.214 patients were 
included, 832.129 women (61.7%). The age mean was 64.3 years (standard deviation 
(SD) 13.2), 50% of patients were between 60 and 74 years old. 94% had diagnosis of HT 
and 26% of DM. The intraclass correlation coefficient (ICC) between CG and DMRD 
was 0.704 with 95% of (0.703- 0.705) with a difference mean of 3.5 and Bland and 
Altman agreed limits from -31.65 to 43.83; ICC being CG and CKD-EPI is 0.728 with 
a CI 95% (0.729-0.730) with a difference mean of 1.73 and Bland and Altman agreed 
limits from -37.26 to 40.62 and correlation coefficient being intraclass CKD-EPI and 
MDRD is 0.855 with 95% of (0.855, 0.856) with a difference mean of -1.86 and Bland 
and Altman agreed limits from -25.61 and 21.89. cOnclusiOns: General popula-
tion studies have reported a good correlation comparison between DRMD and CKD 
-EPI, our results in CKD population and precursor disease, also have shown a good 
correlation between them. Similar findings have been observed in other reports. 
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cost of each stage of kidney disease according scheduled visits in each condition, 
and, therefore, to calculate the economic burden of one year dialysis for the Spanish 
Health System, to check the advantage of a treatment that could delay the disease 
progression of ADPKD. MethOds: The model was based in normal practice of a 
specific hospital, selected for it’s expertise within ADPKD. To build the model the 
following figures were provided: Hospital costs (number of expected healthcare 
provider visits, analytics, image diagnosis), and other expected costs (such ambu-
lance transport and concomitant treatments for hypertension, hypercholester-
olemia, hyperuricemia, pain, infections, and haematuria). In addition to this, costs 
from the patient’s perspective, namely medication and transport costs were also 
analysed. Results: The annual cost for dialysis patients in Hospital La Paz, and 
Madrid Province, in general, is 56,028 euros (43,980.00 € for Hospital costs, up to 600 
€ for medication, and 11,448 € for ambulance transport) , while the rest of Chronic 
Kidney Disease stages (CKD stages 1-4) range annually between 809-1.551 € (Hospital 
costs and medication). Therefore, avoiding 1 year of dialysis will represent around 
54,800 € savings. ADPKD patients cover additional expenses (up to 350 € for medi-
cation and 8-195 € for transport, annually). cOnclusiOns: Dialysis extensively 
increases the economic burden of ADPKD, this is mainly seen in the healthcare 
system. ADPKD patients are faced with medication costs and travel expenses, as 
well as other incommodities and non-calculated indirect costs. Therefore, a treat-
ment able to delay the disease progression represents an important step towards 
patient wellbeing and big savings for the Health System
PUK9
do soCioeConoMiC ineqUalities iMPaCt the soCial Cost of ChroniC 
Kidney disease in italy?
Bellelli S, Turchetti G
Scuola Superiore Sant’Anna, Pisa, Italy
Objectives: The cross sectional study aims to estimate the impact of socio-
economic determinants, such as education and employment status, on the social 
cost of a patient with chronic kidney disease (CKD) stage IV and V pre-dialyses in 
Italy MethOds: Individual socio-economic and clinical data have been collected 
for all adult outpatients in charge of 14 main Hospitals Centers in Tuscany Region 
during 7 weeks between 2012 and 2013. Direct medical costs have been estimated 
using tariff for laboratory test, diagnostic exams, visits and hospitalization and 
price for drugs. The cost of diet, patients and caregivers travel expenses, formal and 
informal care have been evaluated as direct non medical costs. The human capital 
approach has been used for estimating the loss of productivity of patients and 
caregivers. The incremental effects of socio-economic determinants on social cost 
of CKD were estimated by multivariate Generalized Linear Models (log link, Gamma 
family) adjusting for gender, age and stage of disease. Results: No qualification 
and low levels of educations and non-working status characterized, respectively, 
the 54% and 89% of 484 patients enrolled. The raw estimated mean annual social 
costs were € 9,855 (± € 6,826) per patient with CKD. Direct medical costs amounted 
to € 4,352 (± 4,071), representing the 44% of the overall cost, while direct non medi-
cal costs and indirect costs accounted for 30% and 26% (€ 2.912 ± € 3,823 and € 2,590 
± € 3,210). The incremental effect of non-working status on direct medical cost 
was € 1.321 (95% CI: 121-2.520, p< 0,05). Employment condition and high levels of 
education had an incremental effect on indirect costs of € 2.616 (95% CI: 391-4.841, 
p< 0,05) and € 1.039 (95% CI: 135-1.943, p< 0,05). cOnclusiOns: Socio-economic 
inequalities lead to a significant increase of direct medical cost of CKD. High edu-
cation and employment status of patients significantly increase the indirect cost 
component of CKD social cost.
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bAckgROund: Overactive bladder (OAB) symptoms still are not treated in Russian 
Federation in most cases though several medicines are available at the pharmaceuti-
cal market. Direct and indirect costs associated with treatment are important for 
decision makers in health care. Objectives: To conduct cost analysis of solifenacin 
for OAB symptoms vs absence of pharmacotherapy from the Russian government 
perspective. MethOds: A mathematical model was constructed to calculate direct 
and indirect costs associated with OAB for 1 year. Direct medical costs included 
OAB treatment with solifenacin when relevant, urine pads, treatment of compli-
cations and concomitant conditions (CCC) such as urinary infections, skin rash, 
depression and fractures. Indirect costs included productivity losses in patients 
of working ages. Data on incidence of CCC for solifenacin treatment and no treat-
ment strategies was derived from clinical studies. One-way sensitivity analysis was 
performed. Results: Direct medical costs are higher for soilifenacin strategy vs 
no treatment: € 567 and € 483 respectively with cost difference of € 84 per patient per 
year. But solifenacin appears to be cost saving strategy vs no treatment when total 
costs are taken into account: cost difference is € 40 per patient per year in favor of 
solifenacin. Solifenacin remains cost-saving option until the cost of urinary pads 
decreases twice from baseline or the solifenacin efficacy becomes less for 15% from 
baseline. cOnclusiOns: Solifenacin seems to be an acceptable option for Russian 
healthcare from the government perspective.
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Cost-ConseqUenCes analysis of fesoterodine at flexiBle-dose in the 
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prescribed significantly higher number of drugs compared to those without diabetes 
and age ≤ 50 years. The top three prescribed medication groups were antianemic 
preparations (B03), minerals (A12) and vitamins (A11). Vitamin D analogues were 
prescribed to 31.3% of the patients. The predominantly prescribed vitamin D analogue 
was calcitriol. Around 91% of the patients were prescribed phosphate binders (PB). 
Calcium carbonate (88.8%) was the most commonly prescribed phosphate binder, 
whereas sevelamer and lanthanum were seldom prescribed. None of the patients 
was prescribed calcium acetate and aluminum-based PB. cOnclusiOns: Patients 
with CKD stage 5D are prescribed higher number and variety of drugs for the man-
agement of comorbidities associated with kidney disease. Although non-calcium/
non-aluminum based PB have less side effects as compared to calcium-based PB, 
they are seldom prescribed.
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Ahlawat R1, Tiwari P1, D’Cruz S2, Singhal R3
1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), 
Punjab, India, 2Government Medical College & Hospital, Chandigarh, India, 3Independent Health 
and Outcome Researcher, S.A.S. Nagar (Mohali), Punjab, India
Objectives: Chronic kidney disease (CKD) is one of the most commonly occurring 
non-communicable diseases in India. CKD is associated with significant morbidity, 
mortality and economic burden in India. The objective of the present study is to 
estimate the prevalence of CKD in India. MethOds: A systemic search of published 
literature was carried out using PubMed, Elsevier ScienceDirect, Cochrane library 
databases and Google scholar (from 1990 to April 2015) by two independent review-
ers. Reference list of the related articles was also screened to find out the relevant 
studies. CKD definition of KDIGO guideline was used for inclusion criteria. Cochrane 
Q-statistics test and I2 statistics were used to assess the heterogeneity. Random 
effect model was used. Comprehensive Meta-Analysis software (Version 2.2, Biostat, 
Englewood NJ) was used. Results: Five studies were selected as per inclusion crite-
ria. These studies covered the different geographical regions in India. The numbers 
of participants ranged from 2091 to 5588. Pooled rate estimates suggest that 56.11% 
(95% CI, 48.46-63.75) of the patients were male. Hypertension and diabetes were 
found to be the most common comorbidities according to overall pooled estimates 
[48.67 (95% CI, 19.30-78.05) and 17.39 (95% CI, 6.67-28.12), respectively]. Modification 
of Diet in Renal Disease (MDRD) formula for GFR calculation was used by all studies. 
According to MDRD, CKD pooled prevalence in people over 18 years was found to be 
2.97% (95% confidence interval [CI], 1.38%-4.56%). However, Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula was used by two studies and pooled 
prevalence found to be 3.51%. Overall prevalence of end stage renal disease (ESRD) 
was 0.27% (95% CI, 0.06%-0.48%). Pooled estimate for the prevalence of protein urea 
was 6.98% (95% CI, 2.04%-11.91%). cOnclusiOns: The prevalence of CKD, according 
to MDRD and CKD-EPI was 3% and 4%, respectively. Hypertension was found to be 
most commonly occurring co-morbidity (49%). About 7% of the Indian patients were 
found to have proteinuria.
Urinary/Kidney disorders – Cost studies
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Objectives: Our goal was to analyze the rising utilization and to provide a com-
parison between expected number of patients and expenditures described in the 
submitted budget impact analysis and the real expenditures of mirabegron for 
treatment of overactive bladder since its introduction in the Czech Republic in 
January 2014. MethOds: The data source for our analysis was the business activ-
ity monitoring database of the General Health Insurance Company of the Czech 
Republic (VZP CR). VZP CR covers approximately 60 % of marketshare in the Czech 
Republic. Patient was defined as an insured person with a recorded prescription 
for mirabegron (G04BD12) during the observed period 01-12/2014. We identified 
the number of patients treated with mirabegron in the observed period and deter-
mined the real expenditures. We compared the real data with submitted BIA predic-
tions. Results: Since the introduction of mirabegron in January 2014 its utilization 
rose to 1.870 million DDD till 12/2014. There were 11 437 patients treated with mira-
begron and the real expenditures of VZP CR representing 60% were € 2.6 million 
(1EUR= 27,24CZK) in 2014, which strongly differed from the predicted number of 
patients (2026) and expenditures (€ 672t-€ 1.mil) presented in the base case budget 
impact analysis in the reimbursement decision published by State Institute of Drug 
Control (SUKL). cOnclusiOns: There was a significant difference between expen-
ditures predicted in the submitted budget impact analysis and real expenditures. 
The real expenditures were almost 4 times higher than the base case predictions 
(2,5x higher when calculated with cost per patient estimation by SUKL) and more 
than 30% higher than the upper predictions for the first year. Expenditures in the 
first quarter 2015 (€ 1,5 million) have already reached the predictions for the whole 
2015 according the base case. Further analysis will follow to confirm this trend.
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Objectives: Autosomal Dominant Polycystic Kidney Disease (ADPKD) imposes a 
significant economic burden on healthcare systems, particularly in advanced stages 
(5 or End Stage Renal Disease, ESRD). The aim of this model is to study the usual 
